Study of AMMA Portable Scalp Cooling System for Hair Loss in Breast Cancer
This study is looking at how well the AMMA Portable Scalp Cooling System (PSCS) can prevent hair loss in women with early-stage breast cancer who are receiving chemotherapy (CT). The AMMA system is a device you can use at the chemotherapy center, during travel, and at home. Researchers also want to understand how safe and easy the device is to use, and how it affects your quality of life and satisfaction with your hair. You may be able to join if you are a woman at least 21 years old with stage I, II, or III breast cancer, and are scheduled to receive a specific type of chemotherapy. The study will measure hair loss after 3 weeks of treatment. The study is currently enrolling about 99 participants.
- Study design
- This is a study that will enroll about 99 women with early-stage breast cancer. It is designed to assess the AMMA Portable Scalp Cooling System's ability to prevent hair loss.
- What's involved
- You would participate in training on how to use the AMMA device. You would bring the device to each chemotherapy visit and use it for 30 minutes before, during, and at least 2.5 hours after chemotherapy. Scalp photos will be taken at the start and after your last chemotherapy treatment.
- Compensation
- Not stated in the trial record.
- Follow-up
- Hair loss will be measured at 3 weeks after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
At a glance
Conditions
Where it's being run
2 sites across 2 statesStudy leadership
- Kate Dilligan · PRINCIPAL_INVESTIGATOR · Cooler Heads Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Hair Loss3 Weeks
To evaluate hair loss as assessed by the investigator at 3 weeks (±1 week) after the completion of the last CT treatment/infusion visit using the Common Terminology Criteria for Adverse Events (CTCAE) post-treatment, by photographs, compared to baseline photographs.